Compare DLY & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DLY | EMBC |
|---|---|---|
| Founded | 2019 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 707.0M | 719.7M |
| IPO Year | N/A | N/A |
| Metric | DLY | EMBC |
|---|---|---|
| Price | $14.65 | $11.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $18.50 |
| AVG Volume (30 Days) | 215.9K | ★ 664.0K |
| Earning Date | 01-01-0001 | 11-25-2025 |
| Dividend Yield | ★ 8.93% | 5.20% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.62 |
| Revenue | N/A | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | N/A | $0.09 |
| P/E Ratio | ★ N/A | $7.12 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.26 | $9.20 |
| 52 Week High | $15.95 | $21.23 |
| Indicator | DLY | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 33.78 |
| Support Level | $14.53 | $11.02 |
| Resistance Level | $14.67 | $12.56 |
| Average True Range (ATR) | 0.11 | 0.74 |
| MACD | 0.03 | -0.22 |
| Stochastic Oscillator | 79.59 | 12.97 |
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.